Cargando…

Ten Years of CRISPRing Cancers In Vitro

SIMPLE SUMMARY: There are several ways to mimic cancer cells features, one of those being permanently editing their DNA. Even though cancer cells alone cannot represent the whole complexity that develops around them in their surroundings, their modification, characterization and employment in rather...

Descripción completa

Detalles Bibliográficos
Autores principales: Capoferri, Davide, Filiberti, Serena, Faletti, Jessica, Tavani, Camilla, Ronca, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738354/
https://www.ncbi.nlm.nih.gov/pubmed/36497228
http://dx.doi.org/10.3390/cancers14235746
_version_ 1784847520275365888
author Capoferri, Davide
Filiberti, Serena
Faletti, Jessica
Tavani, Camilla
Ronca, Roberto
author_facet Capoferri, Davide
Filiberti, Serena
Faletti, Jessica
Tavani, Camilla
Ronca, Roberto
author_sort Capoferri, Davide
collection PubMed
description SIMPLE SUMMARY: There are several ways to mimic cancer cells features, one of those being permanently editing their DNA. Even though cancer cells alone cannot represent the whole complexity that develops around them in their surroundings, their modification, characterization and employment in rather simplified tests constitutes a fundamental step prior to contextualize them in living models, such as mice, both to comply with the 3Rs rule, and to optimize the in vivo works. On such notes, this review aims to highlight all the processes and discoveries with a long-term intention to make cancers more curable. ABSTRACT: Cell lines have always constituted a good investigation tool for cancer research, allowing scientists to understand the basic mechanisms underlying the complex network of phenomena peculiar to the transforming path from a healthy to cancerous cell. The introduction of CRISPR in everyday laboratory activity and its relative affordability greatly expanded the bench lab weaponry in the daily attempt to better understand tumor biology with the final aim to mitigate cancer’s impact in our lives. In this review, we aim to report how this genome editing technique affected in the in vitro modeling of different aspects of tumor biology, its several declinations, and analyze the advantages and drawbacks of each of them.
format Online
Article
Text
id pubmed-9738354
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97383542022-12-11 Ten Years of CRISPRing Cancers In Vitro Capoferri, Davide Filiberti, Serena Faletti, Jessica Tavani, Camilla Ronca, Roberto Cancers (Basel) Review SIMPLE SUMMARY: There are several ways to mimic cancer cells features, one of those being permanently editing their DNA. Even though cancer cells alone cannot represent the whole complexity that develops around them in their surroundings, their modification, characterization and employment in rather simplified tests constitutes a fundamental step prior to contextualize them in living models, such as mice, both to comply with the 3Rs rule, and to optimize the in vivo works. On such notes, this review aims to highlight all the processes and discoveries with a long-term intention to make cancers more curable. ABSTRACT: Cell lines have always constituted a good investigation tool for cancer research, allowing scientists to understand the basic mechanisms underlying the complex network of phenomena peculiar to the transforming path from a healthy to cancerous cell. The introduction of CRISPR in everyday laboratory activity and its relative affordability greatly expanded the bench lab weaponry in the daily attempt to better understand tumor biology with the final aim to mitigate cancer’s impact in our lives. In this review, we aim to report how this genome editing technique affected in the in vitro modeling of different aspects of tumor biology, its several declinations, and analyze the advantages and drawbacks of each of them. MDPI 2022-11-23 /pmc/articles/PMC9738354/ /pubmed/36497228 http://dx.doi.org/10.3390/cancers14235746 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Capoferri, Davide
Filiberti, Serena
Faletti, Jessica
Tavani, Camilla
Ronca, Roberto
Ten Years of CRISPRing Cancers In Vitro
title Ten Years of CRISPRing Cancers In Vitro
title_full Ten Years of CRISPRing Cancers In Vitro
title_fullStr Ten Years of CRISPRing Cancers In Vitro
title_full_unstemmed Ten Years of CRISPRing Cancers In Vitro
title_short Ten Years of CRISPRing Cancers In Vitro
title_sort ten years of crispring cancers in vitro
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738354/
https://www.ncbi.nlm.nih.gov/pubmed/36497228
http://dx.doi.org/10.3390/cancers14235746
work_keys_str_mv AT capoferridavide tenyearsofcrispringcancersinvitro
AT filibertiserena tenyearsofcrispringcancersinvitro
AT falettijessica tenyearsofcrispringcancersinvitro
AT tavanicamilla tenyearsofcrispringcancersinvitro
AT roncaroberto tenyearsofcrispringcancersinvitro